A Study of LY4065967 in Healthy Japanese Participants

Sponsor
Eli Lilly and Company
Study ID
NCT06594159
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • LY4065967 — DRUG
    Administered orally
  • Placebo — DRUG
    Administered orally
  • Rosuvastatin — DRUG
    Administered orally

Study Details

The purpose of this study is to obtain safety and tolerability data of the study drug known as LY4065967 and rosuvastatin in healthy Japanese participants. Blood tests will be performed to check how much LY4065967 and rosuvastatin get into the bloodstream and how long it takes the body to eliminate it. This is a 3-part study and will last approximately 2 weeks excluding screening period for each part.

Key Dates

Start date
Oct 22, 2024
Status verified
Mar 2025
Primary completion
Mar 11, 2025
Completion
Mar 11, 2025

Study Design

Enrollment
59 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY4065967 Part A
    A single dose of LY4065967 administered orally
  • Placebo Comparator: Placebo Part A
    Placebo administered orally
  • Experimental: LY4065967 Part B
    Multiple doses of LY4065967 administered orally
  • Placebo Comparator: Placebo Part B
    Placebo administered orally
  • Experimental: LY4065967 and Rosuvastatin Part D
    LY4065967 and Rosuvastatin administered orally

Primary Outcome Measure

Part A: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered to be Related to Study Drug Administration [ Time Frame: Baseline to 7 Days ]

Related Studies